Using Flavonoids to Kill Hepatitis B Virus

NCT07084948 | Completed Phase 4 DMC FDA Drug

• 1 other identifier: SB Flavon
• Study Type: interventional
• Target: 134
• Locations: 2 countries
• Sites: 2

Brief Summary

The composition treats Acute Hepatitis, Chronic Hepatitis, Cirrhosis, and hepatocellular carcinoma (S.B.Flavonoids) at an early stage. The product is ascorbic acid, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, and Rutin. These components have participated in protecting liver cell membranes, focusing on reducing liver stress and supporting their structure, repairing and regenerating new liver parenchyma, preventing fibrosis cell generation, and preventing liver cancer cell growth at an early stage. The composition supplements precursors that help the body strengthen antibodies and reduce the risk of inflammation, and restore the physiological and biochemical functions of liver cells after chronic inflammation.

Conditions

Hepatitis B Virus Infection

Keywords

Acid Ascorbic; L-Arginine hydrochloride; Urinariaflavone; 5,6-dihydroxy-7,8,4'-trimethoxy-flavone; Quercetin; Rutin; Kaempferol

Outcome Measures

Primary Outcomes (1)

• Quantification of HBV-DNA, SGPT, SGOT. The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis

  HBV injure healthy liver cells, causing cell death and inflammation. Healthy liver tissue is replaced with scar tissue and the liver is damaged.

  36 months

Secondary Outcomes (1)

• The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis/Hcc (Arm 2)

  36 months

Study Arms (2)

Tenofovir 300mg + SB Flavon

EXPERIMENTAL

Experimental benefits in resistance to the Hepatitis B Virus were observed in all patients who had previously received certain components of the treatment for acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma to Tenofovir + SB Flavon for various therapeutic purposes.

Drug: Flavonoid; Drug: Tenofovir

Tenofovir 300mg

EXPERIMENTAL

Experimental benefits in resistance to the Hepatitis B Virus were observed in all patients who received the treatment with only Tenofovir for various therapeutic purposes.

Drug: Tenofovir

Interventions

Flavonoid DRUG

The daily maintenance, Tenofovir 150mg + SB Flavon 1345mg dose is to be taken 2 times a day, 1 tablet each time. The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma at an early stage. The product is Acid ascorbic, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, Rutin. Use these ingredients to protect liver cell membranes, preventing the growth of HBV in the body.

Also known as: Tenofovir + SB Flavon

Tenofovir 300mg + SB Flavon

Tenofovir DRUG

The daily maintenance, Tenofovir 300mg dose is to be taken 1 time a day, 1 tablet each time. The composition treats acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Tenofovir 300mg; Tenofovir 300mg + SB Flavon

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients with underlying medical conditions who have been taking medications for these conditions.
• Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
• The cancer patients are stable.
• Patients with congenital or acquired immunodeficiency.

You may not qualify if:

• Unstable cancer patients.
• Decompensated cirrhosis.

Sponsors & Collaborators

• Trieu, Nguyen Thi, M.D.: lead

Study Sites (2)

Saigon Biopharma LLC

Wilmington, Delaware, 19801-6601, United States

Location

Saigon Biopharma Company Limited

Hồ Chí Minh, Ho Chi Minh City, 700000, Vietnam

Location

MeSH Terms

Conditions

Hepatitis B

Interventions

Flavonoids; Tenofovir

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepadnaviridae Infections; DNA Virus Infections; Virus Diseases; Hepatitis, Viral, Human; Hepatitis; Liver Diseases; Digestive System Diseases

Intervention Hierarchy (Ancestors)

Chromones; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Organophosphonates; Organophosphorus Compounds; Organic Chemicals; Adenine; Purines

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDIV
• Responsible Party: SPONSOR
• Expanded Access: Yes

Study Record Dates

• First Submitted: July 3, 2025
• First Posted: July 25, 2025
• Study Start: November 30, 2015
• Primary Completion: October 10, 2021
• Study Completion: June 20, 2025
• Last Updated: September 11, 2025

Record last verified: 2025-09

Locations

VN (1); US (1)